Molecular Diagnostics Market
Molecular Diagnostics Market
$4,750.00
Molecular diagnostics is being applied to an increasingly wide range of applications in infectious disease, oncology, and genetic disease diagnosis and screening and to a number of emerging applications in other diseases. The global market for molecular diagnostics is expected to grow at a CAGR of 10.8% between 2019 and 2024, reaching a value of more than $12bn.
Publisher: Meddevicetracker
- Highlights
- Description
- Contents
Highlights
- Molecular diagnostics is being applied to an increasingly wide range of applications in infectious disease, oncology, and genetic disease diagnosis and screening, and to a number of emerging applications in other diseases.
- The global market for molecular diagnostics is expected to grow at a CAGR of 10.8% during the forecast period, reaching a value of more than $12bn by 2024.
- The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing via molecular methods, but other market segments are also experiencing significant growth.
- The leading competitors in the market include Roche, Danaher, bioMérieux, Qiagen, and Hologic, among others.
Key topics
- overview of molecular diagnostics technology, including companion diagnostics
- product portfolios offered by leading manufacturers disease prevalence data
- blood collection trends
- in-depth market and competitive analyses.
Overview
Molecular diagnostics is being applied to an increasingly wide range of applications in infectious disease, oncology, and genetic disease diagnosis and screening and to a number of emerging applications in other diseases. The global market for molecular diagnostics is expected to grow at a CAGR of 10.8% between 2019 and 2024, reaching a value of more than $12bn. The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing via molecular methods, but other segments are also experiencing significant growth. Leading competitors in the market include Roche, Danaher, bioMérieux, Qiagen, and Hologic, among others.
This comprehensive medical market and technology report provides:
- an overview of molecular diagnostics technology, including companion diagnostics
- in-depth market and competitive analyses
- product portfolios offered by leading manufacturers
- disease prevalence data
- blood collection trends
Markets covered by this analysis include the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets.
Table of Contents
Executive Summary………………………………………………………………………….ES-1
i. In vitro molecular diagnostics market…………………………………………………………………………..ES-1
a. Selected market drivers and limiters………………………………………………………….ES-4
b. Technology trends …………………………………………………………………………………..ES-4
c. Market leaders………………………………………………………………………………………..ES-4
ii. Methodology ……………………………………………………………………………………………………………ES-6
Exhibit ES-1: Molecular diagnostics products, combined market forecast ($m), by region, 2019–24 …………………………………………………………………………………………………………ES-2
Exhibit ES-2: Molecular diagnostics products, combined market forecast ($m), by product segment, 2019–24 …………………………………………………………………………………………………………ES-3
1. Molecular Diagnostics Clinical Overview…………………………………………..1-1
1.1 Molecular diagnostics for infectious disease testing……………………………………………………. 1-1
1.1.1 Hepatitis B virus…………………………………………………………………………. 1-3
1.1.2 Hepatitis C virus…………………………………………………………………………. 1-3
1.1.3 Human immunodeficiency virus…………………………………………………… 1-3
1.1.4 Tuberculosis ……………………………………………………………………………… 1-4
1.1.5 Chlamydia trachomatis/Neisseria gonorrhoea ………………………………. 1-4
1.1.6 Human papillomavirus……………………………………………………………….. 1-6
1.1.7 Methicillin-resistant Staphylococcus aureus………………………………….. 1-7
1.1.8 Novel coronavirus (COVID-19) …………………………………………………….. 1-7
1.1.9 Other infectious diseases……………………………………………………………. 1-9
1.2 Molecular diagnostics for oncology testing………………………………………………………………. 1-10
1.2.1 Prostate cancer ……………………………………………………………………….. 1-14
1.2.2 Breast cancer…………………………………………………………………………… 1-14
1.2.3 Colorectal cancer……………………………………………………………………… 1-15
1.2.4 Other cancers………………………………………………………………………….. 1-15
1.3 Molecular diagnostics for genetic testing…………………………………………………………………. 1-17
1.4 Molecular diagnostics for blood screening……………………………………………………………….. 1-20
1.5 Molecular diagnostics for other applications……………………………………………………………. 1-21
1.5.1 Cardiovascular disease……………………………………………………………………….. 1-22
1.5.2 Diabetes…………………………………………………………………………………………… 1-23
1.5.3 Other applications……………………………………………………………………………… 1-24
1.6 Bibliography …………………………………………………………………………………………………………. 1-26
Exhibit 1-1: Epidemiology of selected infectious diseases, by region…………………………………………. 1-5
Exhibit 1-2: Daily SARS-CoV-2 molecular test volume in the US ………………………………………………… 1-9
Exhibit 1-3: Incidence of selected cancer types, by region, 2018 …………………………………………….. 1-12
Exhibit 1-4: Incidence of selected cancer types, by region, 2040 …………………………………………….. 1-13
Exhibit 1-5: Epidemiology of selected genetic diseases, by region…………………………………………… 1-18
Exhibit 1-6: Blood collection trends (‘000), by region, 2011–17 ………………………………………………. 1-21
Exhibit 1-7: Cardiovascular disease mortality (‘000), by region, 2011–16…………………………………. 1-22
Exhibit 1-8: Prevalence of diabetes (‘000), by region, 2010–45……………………………………………….. 1-23
Exhibit 1-9: Organ transplantation procedures, by region, 2014–18………………………………………… 1-25
2. Molecular Diagnostics Products………………………………………………………2-1
2.1 Technology insights…………………………………………………………………………………………………. 2-1
2.1.1 Polymerase chain reaction……………………………………………………………………. 2-1
2.1.2 Hybridization………………………………………………………………………………………. 2-2
2.1.3 Next-generation sequencing…………………………………………………………………. 2-2
2.1.4 Microarray technologies………………………………………………………………………. 2-3
2.1.5 Other technologies ……………………………………………………………………………… 2-3
2.2 Molecular diagnostics products for infectious disease testing ……………………………………… 2-5
2.3 Molecular diagnostics products for oncology testing…………………………………………………… 2-7
2.4 Molecular diagnostics products for genetic testing …………………………………………………… 2-12
2.5 Molecular diagnostics products for blood screening………………………………………………….. 2-15
2.6 Molecular diagnostics products for other applications………………………………………………. 2-16
2.7 Bibliography …………………………………………………………………………………………………………. 2-18
Exhibit 2-1: Selected molecular diagnostics products for infectious disease testing, 2020……………. 2-5
Exhibit 2-2: Selected molecular diagnostic products for oncology testing, 2020 …………………………. 2-9
Exhibit 2-3: Selected molecular diagnostics products for genetic testing, 2020…………………………. 2-13
Exhibit 2-4: Selected molecular diagnostics products for blood screening, 2020……………………….. 2-15
Exhibit 2-5: Selected molecular diagnostics products for other applications, 2020 ……………………. 2-16
3. Molecular Diagnostics Market………………………………………………………..3-1
3.1 Regional insights…………………………………………………………………………………………………….. 3-1
3.1.1 US ……………………………………………………………………………………………. 3-1
3.1.2 Five major European markets……………………………………………………… 3-3
3.1.3 Japan………………………………………………………………………………………… 3-3
3.1.4 Rest of World…………………………………………………………………………….. 3-3
3.2 Molecular diagnostics, market forecast by product segment……………………………………….. 3-4
3.2.1 Competitive analysis……………………………………………………………………………. 3-6
3.3 Trends in the molecular diagnostics products market …………………………………………………. 3-8
3.3.1 Reimbursement/economic …………………………………………………………………… 3-8
3.3.2 Laboratory-developed tests………………………………………………………………….. 3-8
3.4 Market drivers and limiters ……………………………………………………………………………………. 3-10
3.5 Molecular diagnostic products for infectious disease testing, market analysis……………… 3-10
3.5.1 Competitive analysis ………………………………………………………………… 3-13
3.6 Molecular diagnostics for oncology testing, market analysis………………………………………. 3-14
3.6.1 Competitive analysis ………………………………………………………………… 3-16
3.7 Molecular diagnostics for genetic testing, market analysis…………………………………………. 3-17
3.7.1 Competitive analysis ………………………………………………………………… 3-20
3.8 Molecular diagnostics for blood screening, market analysis……………………………………….. 3-21
3.8.1 Competitive analysis ………………………………………………………………… 3-23
3.9 Molecular diagnostics for other applications, market analysis……………………………………. 3-24
3.9.1 Competitive analysis ………………………………………………………………… 3-27
3.10 Bibliography………………………………………………………………………………………………………… 3-28
Exhibit 3-1: Molecular diagnostics products, combined market forecast ($m), by region, 2019–24……………………………………………………………………………………………………………. 3-2
Exhibit 3-2: Molecular diagnostics products, combined market forecast ($m), by segment, 2019–24……………………………………………………………………………………………………………. 3-5
Exhibit 3-3: Molecular diagnostics products, combined market, global share by supplier, 2019 ………………………………………………………………………………………………………………… 3-7
Exhibit 3-4: Molecular testing services/LDT market ($m), 2017–19 …………………………………………… 3-9
Exhibit 3-5: Molecular diagnostics products for infectious disease testing, market forecast ($m), by geographic region, 2019–24 …………………………………………………………………………. 3-12
Exhibit 3-6: Molecular diagnostics products for infectious disease testing, global share by supplier, 2019 ………………………………………………………………………………………………………………. 3-14
Exhibit 3-7: Molecular diagnostics products for oncology testing, market forecast ($m), by region, 2019–24………………………………………………………………………………………………………….. 3-15
Exhibit 3-8: Molecular diagnostics products market for oncology testing, share by supplier, 2019 ………………………………………………………………………………………………………………. 3-17
Exhibit 3-9: Molecular diagnostics products for genetic testing, market forecast ($m), by region, 2019–24………………………………………………………………………………………………………….. 3-19
Exhibit 3-10: Molecular diagnostics products for genetic testing, global share by supplier, 2019……………………………………………………………………………………………………………… 3-20
Exhibit 3-11: Molecular diagnostics products for blood screening, market forecast ($m), by region, 2019–24 ………………………………………………………………………………………… 3-22
Exhibit 3-12: Molecular diagnostics products for blood screening, global share by supplier, 2019……………………………………………………………………………………………………………… 3-23
Exhibit 3-13: Molecular diagnostics products for other applications, market forecast ($m), by region, 2019–24…………………………………………………………………………………………. 3-26
Exhibit 3-14: Molecular diagnostics products for other applications, share by supplier, 2019 …………………………………………………………………………………………………………….. 3-27
APPENDIX: COMPANY LISTING …………………………………………………………………………………… A-1
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Chronic Lymphocytic Leukemia (CLL) KOL Interview – US 
Sign up to the